PRELUDE THERAPEUTICS INC OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
PRELUDE THERAPEUTICS INC (PRLD) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$186.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was -$186.00K.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was -$49.00K.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was $3.00K, a 99.34% decline year-over-year.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-06-30 was -$13.00K.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was -$27.00K.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was -$188.00K, a 109.82% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $1.92M.
- PRELUDE THERAPEUTICS INC oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$981.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$186.00K 10-Q · filed 2026-08-11 | -$235.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$49.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | -$27.00K 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-12 | -$10.00K derived: sum of 2 quarters · filed 2026-08-11 | -$33.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$13.00K 10-Q · filed 2026-08-11 | -$36.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$23.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | -$188.00K 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $457.00K 10-Q · filed 2025-11-12 | $402.00K derived: sum of 2 quarters · filed 2025-11-12 | -$56.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$55.00K 10-Q · filed 2025-11-12 | -$513.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | -$458.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.92M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $106.00K 10-Q · filed 2024-11-06 | -$207.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.09M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$313.00K 10-Q · filed 2024-11-06 | $981.00K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $1.29M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$981.00K 10-K · filed 2024-02-15 | |||
| 2022-09-30 | -$69.00K 10-Q · filed 2023-11-01 | -$50.00K derived: sum of 2 quarters · filed 2023-11-01 | -$1.65M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $19.00K 10-Q · filed 2023-11-01 | -$1.58M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | -$1.60M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | -$711.00K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |